Oethmaan Biosims Pty Limited Pharmaceutical Import Profile — South Africa (DGFT 2022–2026)

Name: Oethmaan Biosims Pty Limited Pharmaceutical Import Records from India — 2 Products, $641.5K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Oethmaan Biosims Pty Limited — Pharmaceutical Importer Profile (2026) | 2 Products, $641.5K Trade | TransData Nexus

Who Are the Verified Indian Suppliers to Oethmaan Biosims Pty Limited?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Milan Laboratories I Private Limited	$841.2K	36	35.9%
Adcock Ingram Limited	$830.1K	59	35.4%
Zeiss Pharma Limited	$464.0K	21	19.8%
V S International Private Limited	$106.2K	3	4.5%
Naprod Life Sciences Private Limited	$54.0K	4	2.3%
Rusan Pharma Limited	$46.3K	1	2.0%

Oethmaan Biosims Pty Limited sources from 6 verified Indian suppliers across 81 distinct formulations. The supply base is diversified across 6 suppliers, reducing single-source dependency risk.

What Formulations Does Oethmaan Biosims Pty Limited Import?

Formulation	Value	Ships
Donapan 500MG TAB paracetamol 500MG TAB	$195.3K	8
Donapan 500MG tablets paracetamol 500MG	$148.6K	5
Carvedilol tablets 12.5 MG Pack: 2x14s	$106.2K	3
Pharma.goods/harmless med:ultramox 500169110pacx1x15=2536650capsamoxycillin trihydrate equivalent to amoxycillin 500MG	$100.0K	2
Pharma goods/harmless	$80.9K	4
Seftry 1.0 g INJ 1x10s batch no. iajl4006a, iajl4007a, iajl4008a, iajl4009a, iajl4010a mfg. dt jan,2024 exp. dt dec	$79.3K	3
Donapan 500MG TAB (paracetamol 500MG tablets)

What Products Does Oethmaan Biosims Pty Limited Import?

Top Products by Import Value

1Flucloxacillin$457.8K 2Glibenclamide$183.7K

Oethmaan Biosims Pty Limited Therapeutic Categories — 2 Specializations

Oethmaan Biosims Pty Limited imports across 2 therapeutic categories, with Advanced Antibiotics (71.4%), Advanced Diabetes Medications (28.6%), representing the largest segments. The portfolio is concentrated — top 5 products = 100% of total imports.

Advanced Antibiotics

1 products · 71.4% · $457.8K

Advanced Diabetes Medications

1 products · 28.6% · $183.7K

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Flucloxacillin	Advanced Antibiotics	$457.8K	10	1.2%	10
2	Glibenclamide	Advanced Diabetes Medications	$183.7K	12	0.3%	6

Key Metrics

Total Import Value$641.5K

Products2

Shipments22

Categories2

CountrySouth Africa

#1 Rankings0

Indian Suppliers6

Formulations81

Top Categories

Advanced Antibiotics71.4%

Advanced Diabetes Medications28.6%

Last updated: March 28, 2026

Oethmaan Biosims Pty Limited — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Oethmaan Biosims (Pty) Ltd. is a fully black-owned pharmaceutical company based in Johannesburg, South Africa. Established in October 2016, it emerged from Medreich SA (Pty) Ltd., a company founded in 2003 with a 74.9% foreign ownership and 25.1% local Black South African ownership. Medreich SA primarily focused on pharmaceutical contract manufacturing from its Indian factories, serving clients such as Adcock Ingram, Sandoz, and private label nutraceuticals for Clicks and Dis-Chem. (oethmaan.co.za)

The company is dedicated to providing affordable and accessible medicines to the broader South African public, covering the entire value chain from manufacturing to distribution. It owns its own intellectual property in the form of medicine dossiers, enabling it to make a significant impact on the provision of affordable medicine. Oethmaan Biosims is particularly focused on biosimilar medicines, addressing the increasing costs of treating chronic diseases like cancer in emerging economies. (oethmaan.co.za)

2Distribution Network

Oethmaan Biosims operates from its headquarters at 207A Sherwood House, Greenacres Office Park, Corner of Rustenburg and Victory Roads, Victory Park, Johannesburg, Gauteng, 2195. While specific details about its warehouse locations and logistics capabilities are not publicly disclosed, the company's strategic position in Johannesburg suggests a centralized distribution model. This location provides access to major transportation routes, facilitating efficient distribution within South Africa and potentially to neighboring countries.

Supplier Relationship Intelligence — Oethmaan Biosims Pty Limited

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Oethmaan Biosims imports finished pharmaceutical formulations from six verified Indian suppliers, with the top four accounting for 95.6% of the total import value. MILAN LABORATORIES I PRIVATE LIMITED leads with 36 shipments valued at $841K (35.9%), followed by ADCOCK INGRAM LIMITED with 59 shipments totaling $830K (35.4%), ZEISS PHARMA LIMITED with 21 shipments amounting to $464K (19.8%), and V S INTERNATIONAL PRIVATE LIMITED with 3 shipments valued at $106K (4.5%). This concentration indicates a strategic choice to maintain stable and reliable supplier relationships, potentially reducing procurement complexities and ensuring consistent product quality. However, such dependency also poses risks; any disruptions with these key suppliers could significantly impact Oethmaan Biosims' ability to meet market demand.

2Supply Chain Resilience

The resilience of Oethmaan Biosims' supply chain is closely tied to its reliance on a limited number of Indian suppliers. While this focus may streamline operations, it also exposes the company to potential risks such as supply disruptions or regulatory changes affecting these suppliers. The diversity of formulations imported—81 unique products—suggests a broad product portfolio, which can mitigate some risks by catering to various therapeutic needs. However, the company's supply chain resilience would benefit from diversifying its supplier base and establishing contingency plans to address potential disruptions.

3Strategic Implications

Oethmaan Biosims' sourcing pattern reflects a strategic emphasis on building strong, long-term relationships with a select group of suppliers, ensuring consistent product quality and supply stability. For Indian exporters, this presents an opportunity to become preferred suppliers by meeting Oethmaan Biosims' quality standards and reliability expectations. However, to mitigate risks associated with supplier concentration, Oethmaan Biosims may consider expanding its supplier network, which could open avenues for additional Indian exporters to enter the South African market.

TransData Nexus Research · Verified DGFT customs dataMar 2026

Importing Pharmaceuticals into South Africa — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for South Africa

1Regulatory Authority & Framework

The South African Health Products Regulatory Authority (SAHPRA) is the primary body responsible for regulating health products, including medicines, in South Africa. SAHPRA operates under the Medicines and Related Substances Act, 1965 (Act No. 101 of 1965), as amended, which provides the legal framework for the regulation of medicines, medical devices, and related substances. This legislation outlines the requirements for the registration, importation, exportation, and distribution of medicines within the country. (sahpra.org.za)

2Import Licensing & GMP

To import medicines into South Africa, companies must obtain a license from SAHPRA, which authorizes them to import and distribute medicines. Additionally, the South African Pharmacy Council requires that pharmaceutical manufacturers and wholesalers be licensed and recorded as manufacturing or wholesale pharmacies. Compliance with Good Manufacturing Practices (GMP) is mandatory, and SAHPRA issues guidelines related to GMP to ensure that medicines meet the required quality standards.

3Quality & Labeling

Imported medicines must undergo batch testing to ensure they meet the required quality standards. Stability requirements are set to ensure that medicines remain effective and safe throughout their shelf life. Labeling must comply with SAHPRA's regulations, including language requirements and the inclusion of necessary information such as dosage instructions, storage conditions, and expiration dates. Serialization mandates may apply to facilitate traceability and prevent counterfeit products. (sahpra.org.za)

4Recent Regulatory Changes

Between 2024 and 2026, SAHPRA has implemented several policy changes affecting the importation of medicines into South Africa. These include updates to the guidelines for the importation and exportation of medicines, emphasizing the need for compliance with international standards and the importance of ensuring the quality, safety, and efficacy of imported medicines. Additionally, SAHPRA has clarified processes for the importation of unregistered medicines under Section 21 of the Medicines Act, allowing for the importation of specific quantities of unregistered medicines for individual patients under strict conditions. (sahpra.org.za)

TransData Nexus Research · South Africa regulatory databasesMar 2026

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Buyer Matching: Oethmaan Biosims Pty Limited identified across shipments using consignee name normalization, aggregating 2 name variants.
2.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
3.Market Share: Calculated per product as Oethmaan Biosims Pty Limited's capped value divided by total Indian exports for that product.
4.Shipment Count: Based on 22 individual customs records matching Oethmaan Biosims Pty Limited.
5.Supplier Verification: Oethmaan Biosims Pty Limited sources from 6 verified Indian suppliers across 81 formulations, confirmed from customs records.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

2 Products Tracked

2 therapeutic categories

Expert-Reviewed

By pharmaceutical trade specialists

Oethmaan Biosims Pty Limited

Oethmaan Biosims Pty Limited — Import Portfolio & Supplier Network

Who Are the Verified Indian Suppliers to Oethmaan Biosims Pty Limited?

What Formulations Does Oethmaan Biosims Pty Limited Import?

What Products Does Oethmaan Biosims Pty Limited Import?

Top Products by Import Value

Oethmaan Biosims Pty Limited Therapeutic Categories — 2 Specializations

Import Portfolio — Top 2 by Import Value

Key Metrics

Top Categories

Oethmaan Biosims Pty Limited — Corporate Profile & Information

1Company Overview

2Distribution Network

Indian Suppliers

Related Trade Data

Need Detailed Data?

3Industry Role

Supplier Relationship Intelligence — Oethmaan Biosims Pty Limited

1Sourcing Concentration Analysis

2Supply Chain Resilience

3Strategic Implications

Importing Pharmaceuticals into South Africa — Regulatory Framework

1Regulatory Authority & Framework

2Import Licensing & GMP

3Quality & Labeling

4Recent Regulatory Changes

Oethmaan Biosims Pty Limited — Procurement Pattern Analysis

1Product Strategy

2Sourcing Profile

3Market Positioning

Seller's Guide — How to Become a Supplier to Oethmaan Biosims Pty Limited

1Opportunity Assessment

2Requirements & Qualifications

3How to Approach

Frequently Asked Questions — Oethmaan Biosims Pty Limited

What products does Oethmaan Biosims Pty Limited import from India?

Who supplies pharmaceuticals to Oethmaan Biosims Pty Limited from India?

What is Oethmaan Biosims Pty Limited's total pharmaceutical import value?

What therapeutic categories does Oethmaan Biosims Pty Limited focus on?

Get Full Oethmaan Biosims Pty Limited Import Intelligence

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

Analysis Methodology

Data Source & Methodology